Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Citagenix Sale Announced this AM

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 04, 2022 5:17pm

234 Views

Post# 34656648

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Citagenix Sale Announced this AM

Jefnan1 wrote: Well I came in at $.54 saw it go to $.08 then to $7 plus. I own 1 million shares so I know what I'm talking about and my opinions of these guys are valid

I have no issues with you opinions.
That's the only way to use these sites - soak in everything and weed out what you don't agree with.
For good or for bad - in the end we own it.

You have a lot of votes you can use to show your displeasure - nothing wrong with that.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity